10 completed, 5 terminated. 15 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 5 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Elan Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia ELND005, Placebo - Down Syndrome | Phase 2 | Completed | OPKO Health, Inc. | 23 | 2013-09-01 | 2019-11-04 |
| A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease Group 1 ELND005, Group 2 ELND005 - Alzheimer's Disease | Phase 2 | Terminated | OPKO Health, Inc. | 296 | 2013-01-01 | 2019-10-21 |
| Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease ELND005, Placebo - Alzheimer's Disease | Phase 2 | Completed | OPKO Health, Inc. | 350 | 2012-11-01 | 2019-10-21 |
| Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder ELND005, Lamotrigine, Valproic acid - Bipolar 1 Disorder | Phase 2 | Terminated | OPKO Health, Inc. | 309 | 2012-08-01 | 2019-10-21 |
| Treatment Interruption of Natalizumab natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 175 | 2010-03-01 | 2013-09-19 |
| Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) mefloquine - Progressive Multifocal Leukoencephalopathy | Phase 1 / Phase 2 | Terminated | Biogen | 37 | 2009-01-01 | 2014-07-31 |
| Natalizumab High Titer Immunogenicity and Safety BG00002-E (natalizumab high titer) - Multiple Sclerosis | Phase 2 | Completed | Biogen | 113 | 2006-10-01 | 2014-05-15 |
| A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 natalizumab - Rheumatoid Arthritis | Phase 2 | Terminated | Biogen | 2004-09-01 | 2016-06-16 | |
| Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate natalizumab, placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Biogen | 299 | 2004-05-01 | 2016-07-18 |
| Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis Natalizumab, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Completed | Biogen | 110 | 2003-06-01 | 2009-06-18 |
| Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease natalizumab - Crohn's Disease | Phase 2 | Completed | Biogen | 60 | 2002-04-01 | 2016-06-16 |
| Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease natalizumab - Crohn's Disease | Phase 2 | Completed | Biogen | 30 | 2002-04-01 | 2016-06-16 |
| A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache zonisamide - Migraine Headache | Phase 2 | Completed | Elan Pharmaceuticals | 204 | 2002-03-01 | 2015-12-14 |
| "DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?" Botulinum Toxin type B - Cerebral Palsy | Phase 1 / Phase 2 | Completed | Stanford University | 10 | 2002-01-01 | 2005-10-13 |
| ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections ISIS 14803 - Hepatitis C, Chronic | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 2001-10-01 | 2022-12-05 |
Aggression (2) · Alzheimer Disease (2) · Arthritis, Rheumatoid (2) · Crohn Disease (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Psychomotor Agitation (2) · Central Nervous System Diseases (1) · Cerebral Palsy (1) · Down Syndrome (1) · Hepatitis C, Chronic (1) · Leukoencephalopathy, Progressive Multifocal (1) · Migraine Disorders (1)
Natalizumab (7) · scyllitol (3) · Glatiramer Acetate (1) · Interferon beta-1a (1) · Lamotrigine (1) · Mefloquine (1) · Methylprednisolone (1) · Valproic Acid (1) · Zonisamide (1) · rimabotulinumtoxinB (1)
United States (13) · Spain (5) · Canada (4) · United Kingdom (3) · Germany (2) · Brazil (1) · Bulgaria (1) · Czechia (1) · France (1) · Italy (1) · Poland (1) · Romania (1) · Turkey (Türkiye) (1)